Wegovy Pill UK: Approval, Cost and Availability Explained

What is the Wegovy pill?

The Wegovy pill is a tablet version of semaglutide, the same medicine used in Wegovy injections. It was approved by the MHRA on 11 June 2026, making it the first GLP-1 receptor agonist tablet licensed for weight loss in the UK.
Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. These medicines mimic a natural hormone your body produces after eating. The hormone helps regulate appetite, slows digestion and signals to your brain that you are full.
The result is reduced hunger, smaller portions and significant weight loss for many patients.
Until June 2026, semaglutide for weight management in the UK was only available as a weekly injection. The new tablet version delivers many of the same benefits without requiring patients to inject themselves, and is now available privately, with most major UK providers taking pre-orders ahead of wider stock availability.
For people who have been put off treatment by needles, this removes one of the biggest barriers to starting.

What did the OASIS-4 trial actually show?

The most important study examining oral semaglutide for weight loss is the OASIS clinical trial programme conducted by Novo Nordisk.
The headline result comes from OASIS-4, which followed adults living with obesity or overweight for 64 weeks.
Participants who remained fully adherent to treatment achieved average weight loss of 16.6 percent of their body weight. Across the full intention-to-treat group, including those who did not stay fully adherent, average weight loss was 13.6 percent. The 13.6 percent figure is the one generally used for comparisons with other treatments, since it reflects real-world adherence rather than a best-case subgroup.
To put that into plain English, someone weighing 16 stone could potentially lose around 2.2 to 2.5 stone if similar results were achieved in real-world use.
That places oral semaglutide among the most effective weight loss tablets ever studied.
The significance of the result becomes clearer when compared with older weight loss medications. Many previous tablets produced modest single-digit weight loss percentages. Oral semaglutide moves far beyond that territory and approaches the effectiveness previously associated only with injectable treatments.
Researchers also reported improvements in waist circumference, blood sugar control and other obesity-related health markers.

Wegovy Pill UK vs Wegovy injections

This is the question most UK patients are actually asking.
Is the tablet as good as the injection?
The honest answer is that both contain the same active ingredient, semaglutide, but they are not identical experiences.
The injection is taken once per week. The tablet is taken once every day.
The daily tablet also comes with stricter instructions. It must be taken first thing in the morning with a small amount of water on an empty stomach. Patients then need to wait at least 30 minutes before eating, drinking or taking other medication.
The weekly injection does not have those restrictions.
For some people, taking a tablet will feel far easier than using an injection pen. For others, remembering a daily tablet may prove more difficult than a once-weekly injection.
In terms of effectiveness, both approaches appear highly effective. The difference for many patients may come down to convenience and personal preference rather than weight loss alone.
Patients already taking the 2.4mg weekly injection privately can, under their prescriber’s direction, transition directly to the 25mg tablet rather than restarting the dose schedule from the beginning.

Wegovy pill vs Wegovy injections vs Mounjaro – which should I choose?

All three are now available in the UK, so this is a genuine three-way choice rather than a question of waiting for anything.
Mounjaro produces the strongest average weight loss of the three, around 20 to 22 percent at its highest dose. The standard Wegovy injection follows, with 14.9 percent at the standard 2.4mg dose and up to 20.7 percent at the newer 7.2mg dose. The Wegovy pill sits at 13.6 percent on an intention-to-treat basis (16.6 percent among fully adherent patients), putting it roughly in line with the standard-dose injection, and below Mounjaro’s top dose.
If maximum average weight loss is the priority, Mounjaro currently leads, with high-dose Wegovy injections close behind.
But effectiveness isn’t the only factor that matters. The Wegovy pill is taken once daily on an empty stomach rather than injected once weekly, which may suit patients who are needle-averse or prefer the routine of a daily tablet over a weekly injection. Both Wegovy formats use semaglutide and target a single hormone receptor, GLP-1, while Mounjaro targets two receptors, GLP-1 and GIP, which is the main driver of its slightly stronger results.
The health risks associated with obesity don’t pause while you decide, so the more useful framing is choosing the treatment that fits your tolerance, preferences and lifestyle, since all three are available today without needing to wait. For the fuller picture, including quality of life, dropout rates and long-term outcomes across all these drugs, see our weight loss jabs and pills compared guide, based on a major 2026 BMJ analysis.

Wegovy pill side effects – what we know so far

The side effect profile of oral semaglutide appears broadly similar to Wegovy injections.
The most commonly reported side effects include nausea, diarrhoea, constipation and vomiting.
These effects are familiar to anyone who has researched GLP-1 medicines. They are typically most noticeable during dose increases and often improve as the body adjusts.
Current evidence does not suggest any major new safety concerns compared with injectable semaglutide, although ongoing monitoring will continue as the treatment becomes more widely used.

What will the Wegovy pill cost in the UK?

Oral Wegovy is priced privately from around £99 to £269 per month depending on dose and provider, broadly comparable to the injection. Lower starting doses cost less; the 25mg maintenance dose sits at the top of the range.
Pricing varies meaningfully between providers, some quote a flat monthly rate, others price each dose strength separately, and several are offering pre-order or first-month discounts ahead of full stock availability. Always check the current price directly with your chosen provider before committing, or see our Mounjaro price comparison for a live sense of how UK GLP-1 pricing generally moves.
NHS access would require a separate NICE assessment following MHRA approval, and is not expected before 2027 at the earliest.

Frequently Asked Questions

This guide is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.